表纸
市场调查报告书
商品编码
1036445

人体微生物治疗药的全球市场(2021年~2025年)

Global Human Microbiome Therapeutics Market 2021-2025

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 120 Pages | 订单完成后即时交付

价格
  • 全貌
  • 简介
  • 目录
简介

全球人体微生物治疗药的市场规模在2021年~2025年的预测期间内,预计将以47.79%的年复合成长率增长,并成长到5亿1,608万美元。

该市场成长的主要因素有慢性疾病的盛行率提升与稳定的开发平台等。

本报告提供人体微生物治疗药的世界市场调查,提供市场规模和预测,市场促进因素及课题,市场机会,应用·各地区的市场分析,业者情势,主要供应商分析等系统性资讯。

目录

摘要整理

市场形势

  • 市场生态系统
  • 价值链分析

市场规模

  • 市场定义
  • 市场区隔分析
  • 市场规模(2020年)
  • 市场规模预测(2020年~2025年)

波特的五力分析

  • 买方议价能力
  • 供给企业谈判力
  • 新加入厂商业者的威胁
  • 替代品的威胁
  • 竞争的威胁
  • 市场情况

各应用领域,市场区隔

  • 市场区隔
  • 各应用领域比较
  • 肠胃障碍
  • 感染疾病
  • 其他
  • 各应用领域的市场机会

客户形势

各地区,市场区隔

  • 各地区市场区隔
  • 各地区比较
  • 北美
  • 欧洲
  • 亚洲
  • 其他地区
  • 主要国家
  • 各地区形势的市场机会
  • 市场推动因素
  • 市场课题
  • 市场趋势

业者情势

  • 概要
  • 创造性破坏状况

供应商分析

  • 交易厂商
  • 供应商的市场定位
  • 4D pharma Plc
  • ENTEROME SA
  • Ferring B.V.
  • Johnson and Johnson Inc.
  • Kaleido Biosciences Inc.
  • OptiBiotix Health Plc
  • PureTech Health Plc
  • Second Genome Therapeutics
  • Seres Therapeutics Inc.
  • Takeda Pharmaceutical Co. Ltd.

附录

目录
Product Code: IRTNTR43730

Technavio has been monitoring the human microbiome therapeutics market and it is poised to grow by $ 516.08 mn during 2021-2025, progressing at a CAGR of 47.79% during the forecast period. Our report on the human microbiome therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of chronic diseases and robust pipeline. In addition, the growing prevalence of chronic diseases is anticipated to boost the growth of the market as well.

The human microbiome therapeutics market analysis includes the application segment and geographic landscape.

Technavio's human microbiome therapeutics market is segmented as below:

By Application

  • Gastrointestinal disorders
  • Infectious diseases
  • Others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the side effects of existing treatmentas one of the prime reasons driving the human microbiome therapeutics market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on human microbiome therapeutics market covers the following areas:

  • Human microbiome therapeutics market sizing
  • Human microbiome therapeutics market forecast
  • Human microbiome therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human microbiome therapeutics market vendors that include 4D pharma Plc, ENTEROME SA, Ferring B.V., Johnson and Johnson Inc., Kaleido Biosciences Inc., OptiBiotix Health Plc, PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., and Takeda Pharmaceutical Co. Ltd. Also, the human microbiome therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

  • Executive Summary
    • Market overview
  • Market Landscape
    • Market ecosystem
    • Value chain analysis
  • Market Sizing
    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025
  • Five Forces Analysis
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
  • Market Segmentation by Application
    • Market segments
    • Comparison by Application
    • Gastrointestinal disorders - Market size and forecast 2020-2025
    • Infectious diseases - Market size and forecast 2020-2025
    • Others - Market size and forecast 2020-2025
    • Market opportunity by Application
  • Customer landscape
  • Geographic Landscape
    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2020-2025
    • Europe - Market size and forecast 2020-2025
    • Asia - Market size and forecast 2020-2025
    • ROW - Market size and forecast 2020-2025
    • Key leading countries
    • Market opportunity By Geographical Landscape
    • Market drivers
    • Market challenges
    • Market trends
  • Vendor Landscape
    • Overview
    • Landscape disruption
  • Vendor Analysis
    • Vendors covered
    • Market positioning of vendors
    • 4D pharma Plc
    • ENTEROME SA
    • Ferring B.V.
    • Johnson and Johnson Inc.
    • Kaleido Biosciences Inc.
    • OptiBiotix Health Plc
    • PureTech Health Plc
    • Second Genome Therapeutics
    • Seres Therapeutics Inc.
    • Takeda Pharmaceutical Co. Ltd.
  • Appendix
    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations

Exhibits

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Application - Market share 2020-2025 (%)
  • 22: Comparison by Application
  • 23: Gastrointestinal disorders - Market size and forecast 2020-2025 ($ million)
  • 24: Gastrointestinal disorders - Year-over-year growth 2020-2025 (%)
  • 25: Infectious diseases - Market size and forecast 2020-2025 ($ million)
  • 26: Infectious diseases - Year-over-year growth 2020-2025 (%)
  • 27: Others - Market size and forecast 2020-2025 ($ million)
  • 28: Others - Year-over-year growth 2020-2025 (%)
  • 29: Market opportunity by Application
  • 30: Customer landscape
  • 31: Market share By Geographical Landscape 2020-2025 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2020-2025 ($ million)
  • 34: North America - Year-over-year growth 2020-2025 (%)
  • 35: Europe - Market size and forecast 2020-2025 ($ million)
  • 36: Europe - Year-over-year growth 2020-2025 (%)
  • 37: Asia - Market size and forecast 2020-2025 ($ million)
  • 38: Asia - Year-over-year growth 2020-2025 (%)
  • 39: ROW - Market size and forecast 2020-2025 ($ million)
  • 40: ROW - Year-over-year growth 2020-2025 (%)
  • 41: Key leading countries
  • 42: Market opportunity By Geographical Landscape ($ million)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: 4D pharma Plc - Overview
  • 50: 4D pharma Plc - Product and service
  • 51: 4D pharma Plc - Key offerings
  • 52: 4D pharma Plc - Key customers
  • 53: 4D pharma Plc - Segment focus
  • 54: ENTEROME SA - Overview
  • 55: ENTEROME SA - Product and service
  • 56: ENTEROME SA - Key offerings
  • 57: ENTEROME SA - Key customers
  • 58: ENTEROME SA - Segment focus
  • 59: Ferring B.V. - Overview
  • 60: Ferring B.V. - Product and service
  • 61: Ferring B.V. - Key offerings
  • 62: Ferring B.V. - Key customers
  • 63: Ferring B.V. - Segment focus
  • 64: Johnson and Johnson Inc. - Overview
  • 65: Johnson and Johnson Inc. - Business segments
  • 66: Johnson and Johnson Inc. - Key offerings
  • 67: Johnson and Johnson Inc. - Key customers
  • 68: Johnson and Johnson Inc. - Segment focus
  • 69: Kaleido Biosciences Inc. - Overview
  • 70: Kaleido Biosciences Inc. - Product and service
  • 71: Kaleido Biosciences Inc. - Key offerings
  • 72: Kaleido Biosciences Inc. - Key customers
  • 73: Kaleido Biosciences Inc. - Segment focus
  • 74: OptiBiotix Health Plc - Overview
  • 75: OptiBiotix Health Plc - Product and service
  • 76: OptiBiotix Health Plc - Key offerings
  • 77: OptiBiotix Health Plc - Key customers
  • 78: OptiBiotix Health Plc - Segment focus
  • 79: PureTech Health Plc - Overview
  • 80: PureTech Health Plc - Business segments
  • 81: PureTech Health Plc - Key offerings
  • 82: PureTech Health Plc - Key customers
  • 83: PureTech Health Plc - Segment focus
  • 84: Second Genome Therapeutics - Overview
  • 85: Second Genome Therapeutics - Product and service
  • 86: Second Genome Therapeutics - Key offerings
  • 87: Second Genome Therapeutics - Key customers
  • 88: Second Genome Therapeutics - Segment focus
  • 89: Seres Therapeutics Inc. - Overview
  • 90: Seres Therapeutics Inc. - Product and service
  • 91: Seres Therapeutics Inc. - Key offerings
  • 92: Seres Therapeutics Inc. - Key customers
  • 93: Seres Therapeutics Inc. - Segment focus
  • 94: Takeda Pharmaceutical Co. Ltd. - Overview
  • 95: Takeda Pharmaceutical Co. Ltd. - Product and service
  • 96: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 97: Takeda Pharmaceutical Co. Ltd. - Key customers
  • 98: Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations